BioInvent International AB (publ)

LSE:0H22 Stock Report

Market Cap: SEK 1.7b

BioInvent International Management

Management criteria checks 3/4

BioInvent International's CEO is Martin Welschof, appointed in Sep 2018, has a tenure of 6.42 years. total yearly compensation is SEK5.17M, comprised of 55.5% salary and 44.5% bonuses, including company stock and options. directly owns 0.034% of the company’s shares, worth SEK566.72K. The average tenure of the management team and the board of directors is 4 years and 5.9 years respectively.

Key information

Martin Welschof

Chief executive officer

SEK 5.2m

Total compensation

CEO salary percentage55.5%
CEO tenure6.4yrs
CEO ownership0.03%
Management average tenure4yrs
Board average tenure5.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Martin Welschof's remuneration changed compared to BioInvent International's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-SEK 410m

Jun 30 2024n/an/a

-SEK 383m

Mar 31 2024n/an/a

-SEK 335m

Dec 31 2023SEK 5mSEK 3m

-SEK 330m

Sep 30 2023n/an/a

-SEK 311m

Jun 30 2023n/an/a

-SEK 304m

Mar 31 2023n/an/a

-SEK 48m

Dec 31 2022SEK 5mSEK 3m

-SEK 43m

Sep 30 2022n/an/a

-SEK 43m

Jun 30 2022n/an/a

-SEK 42m

Mar 31 2022n/an/a

-SEK 266m

Dec 31 2021SEK 5mSEK 3m

-SEK 278m

Sep 30 2021n/an/a

-SEK 171m

Jun 30 2021n/an/a

-SEK 141m

Mar 31 2021n/an/a

-SEK 123m

Dec 31 2020SEK 5mSEK 3m

-SEK 76m

Sep 30 2020n/an/a

-SEK 146m

Jun 30 2020n/an/a

-SEK 150m

Mar 31 2020n/an/a

-SEK 144m

Dec 31 2019SEK 4mSEK 2m

-SEK 139m

Sep 30 2019n/an/a

-SEK 130m

Jun 30 2019n/an/a

-SEK 116m

Mar 31 2019n/an/a

-SEK 126m

Dec 31 2018SEK 3mSEK 800k

-SEK 123m

Compensation vs Market: Martin's total compensation ($USD473.36K) is below average for companies of similar size in the UK market ($USD735.80K).

Compensation vs Earnings: Martin's compensation has increased whilst the company is unprofitable.

CEO

Martin Welschof (63 yo)

6.4yrs

Tenure

SEK 5,167,000

Compensation

Dr. Martin Welschof, Ph D had been the Chief Executive Officer of Opsona Therapeutics Limited since February 2012. Dr. Welschof has been Chief Executive Officer at BioInvent Intl AB (publ) since 2018.He i...

Leadership Team

NamePositionTenureCompensationOwnership
Martin Welschof
President & CEO6.4yrsSEK 5.17m0.034%
SEK 566.7k
Stefan Ericsson
Chief Financial Officer9.1yrsno data0.012%
SEK 202.4k
Marie Moores
Chief Operating Officer3yrsno datano data
Kristoffer Hansson
Senior Vice President of Technical Operations8.4yrsno data0.034%
SEK 564.2k
Björn Frendéus
Chief Scientific Officerno dataSEK 2.35m0.035%
SEK 584.2k
Cecilia Hofvander
Senior Director of Investor Relations4yrsno datano data
Andres McAllister
Chief Medical Officer8.1yrsno data0.0046%
SEK 76.1k
Ingrid Teige
Head of Preclinical Researchno datano datano data
Sylvie Ryckebusch
Chief Business Officer2.7yrsno data0.035%
SEK 578.5k
Ingunn Lindvig
Senior Vice President of Regulatory Affairs1.7yrsno datano data
Ashley Robinson
Senior VP of Strategy & Financeless than a yearno datano data

4.0yrs

Average Tenure

59yo

Average Age

Experienced Management: 0H22's management team is considered experienced (4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Bernd Seizinger
Independent Director7.1yrsSEK 595.00k0.10%
SEK 1.7m
Leonard Kruimer
Independent Chairman of the Board7.1yrsSEK 782.00k0.051%
SEK 848.6k
Thomas Hecht
Independent Director4.6yrsSEK 510.00kno data
Vincent Ossipow
Independent Director3.8yrsSEK 475.00kno data
Alexander Rudensky
Member of Scientific Advisory Board8.1yrsno datano data
Alexander Maximiliaan Eggermont
Member of Scientific Advisory Board3.3yrsno datano data
Falk Nimmerjahn
Member of Scientific Advisory Board8.1yrsno datano data
Kristoffer Bissessar
Independent Director4.8yrsSEK 520.00k0.044%
SEK 733.7k
Rienk Offringa
Member of Scientific Advisory Board8.1yrsno datano data
Mark Cragg
Member of Scientific Advisory Boardno datano datano data
Stephen Beers
Member of Scientific Advisory Boardno datano datano data
Martin Palsson
Employee Representative Director3yrsno datano data

5.9yrs

Average Tenure

61yo

Average Age

Experienced Board: 0H22's board of directors are considered experienced (5.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/10 12:49
End of Day Share Price 2025/02/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BioInvent International AB (publ) is covered by 9 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Morten LarsenABG Sundal Collier
Camilla OxhamreCarnegie Investment Bank AB
Mattias HäggblomDanske Bank